75°F
weather icon Clear

Study offers rare advance for some pancreatic cancer patients

Updated June 25, 2019 - 10:30 pm

CHICAGO — Patients with pancreatic cancer that hadn’t spread lived substantially longer on a four-drug combo than on a single standard cancer drug,

It’s a rare advance for a tough-to-beat cancer, and experts say it could be practice-changing for a small group of patients whose pancreatic cancer is diagnosed early enough to be removed by surgery.

Results were reported Monday at a medical meeting in Chicago.

The study tested folfirinox against the standard treatment, Gemzar. Folfirinox combines four chemotherapy drugs.

Two-thirds of patients given folfirinox were alive after three years versus half of those given Gemzar.

Nearly 500 patients in France and Canada were enrolled.

MOST READ
Don't miss the big stories. Like us on Facebook.
THE LATEST
Want a COVID-19 shot? That’s up to you, vaccine advisory panel says

A panel of advisers appointed by Health Secretary Robert F. Kennedy Jr. declined to recommend this fall’s COVID-19 vaccinations for anyone, leaving the choice up to those who want a shot.

Tips to reduce screen time, start a new hobby

Adopting a new hobby can be an effective way to get a break from screens. Enjoyable pastimes can reduce stress and improve well-being, research suggests.

7 tips to help fight a health insurance denial

Prior authorization denials of medical procedures, tests or prescriptions can be appealed, but many people find the process overwhelming.

Which flu vaccine is best for children?

As a parent, the best thing you can do to protect your children and others from the flu is to get them vaccinated.

 
5 foods you should never eat before a workout

Not all pre-workout food is created equal. Choose wrong, and you can end up struggling to finish your exercise routine.

Do weighted vests really help you get in shape faster?

Weighted vests are increasingly showing up in fitness classes, touted as a way to keep bones healthy, improve performance and boost weight loss.

MORE STORIES